These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Subscribe To Our Newsletter & Stay Updated
